Attention Seniors! It’s Never Too Late to Stop Smoking

Quitting smoking even as late as at 75 years of age can meaningfully increase a person’s life expectancy, according to a new study 打開新的分頁／視窗 in the American Journal of Preventive Medicine 打開新的分頁／視窗, published by Elsevier. The research measures the impact of smoking on life expectancy at 10-year intervals from 35-75 years of age to determine the potential benefits of smoking cessation. The results show that although the benefits of quitting smoking diminish with age, there are still substantial gains for older individuals.

Thuy T.T. Le, PhD, who conducted the study with co-investigators David Mendez, PhD, and Kenneth E. Warner, PhD, all affiliated with the Department of Health Management and Policy at the University of Michigan School of Public Health, explains, "We have seen a remarkable decline in young adult smoking over the past decade. However, rates among older adults who smoke have remained stagnant and to our knowledge, no research had established the benefits for them of quitting. We wanted to show that stopping smoking is beneficial at any age and provide an incentive for older people who smoke to quit.”

Cigarette smoke contains thousands of toxic chemicals that harm almost all organs in the body and are linked to numerous cancers, stroke, heart disease, and lung disease. In the United States cigarette smoking has long been the leading cause of premature preventable death, with an estimated 480,000 smoking-related deaths annually. Previous studies have consistently demonstrated that quitting smoking at any age yields health benefits.

This is the first study to quantify the impact of quitting smoking for individuals older than 65. The investigators used all-cause mortality relative risks due to smoking to build life tables that show the benefits of quitting smoking at different ages. They report the expected life years lost to individuals who smoke at various ages compared to those who never smoked. Compared to people who never smoked, those who smoke currently, aged 35, 45, 55, 65, or 75 years and who have smoked throughout adulthood until that age, will lose on average, 9.1, 8.3, 7.3, 5.9, and 4.4 years of life, respectively, if they continue to smoke for the rest of their lives. However, if they quit smoking at each of these ages, they will avoid an average loss of 8.0, 5.6, 3.4,1.7, and 0.7 years, respectively. The chances of gaining at least one year of life among those who quit at age 65 are 23.4% and 14.2%.at age 75.

This study adds to the body of knowledge supporting the profoundly important assessment that quitting smoking is the single best thing people can do to enhance their life expectancy. Results showed that nearly 10% of individuals who quit at age 65 gain at least 8 years of life compared to those who do not. Additionally, 8% of those who quit by age 75 gain at least 4 years of life compared to those who continue smoking. Life expectancy for a 75-year-old person who smokes is 9 years. If that person quits, he/she will regain (on average) 0.7 years (7.8% of the life expectancy), and about 8% of those individuals who quit will regain at least 4 years of life (45% of the life expectancy).

Dr. Warner concludes, “The cessation benefit is not limited to young and middle-aged adults who smoke; this study demonstrates its applicability to seniors as well. While the gains from quitting at older ages may seem low in absolute values, they represent a large proportion of an individual's remaining life expectancy.”

These findings can assist clinicians seeking scientific evidence to motivate their patients who smoke to quit.

Notes for editors

The article is “The Benefits of Quitting Smoking at Different Ages,” by Thuy T.T. Le, PhD, David Mendez, PhD, and Kenneth E. Warner, PhD (https://doi.org/10.1016/j.amepre.2024.06.020 打開新的分頁／視窗). It appears online in advance of the American Journal of Preventive Medicine, volume 67, issue 5 (November 2024), published by Elsevier.

The article is openly available at https://www.ajpmonline.org/article/S0749-3797(24)00217-4/fulltext 打開新的分頁／視窗.

Full text of this article is also available to credentialed journalists upon request; contact Eileen Leahy at +1 732 406 1313 or [email protected] 打開新的分頁／視窗. Journalists wishing to interview the authors should contact Thuy T.T. Le, PhD, at [email protected] 打開新的分頁／視窗.

The research reported in the study was supported by the National Cancer Institute of the National Institutes of Health and the Food and Drug Administration Center for Tobacco Products (Award Number U54CA229974).

About the American Journal of Preventive Medicine

The American Journal of Preventive Medicine 打開新的分頁／視窗 is the official journal of the American College of Preventive Medicine 打開新的分頁／視窗 and the Association for Prevention Teaching and Research 打開新的分頁／視窗. It publishes articles in the areas of prevention research, teaching, practice and policy. Original research is published on interventions aimed at the prevention of chronic and acute disease and the promotion of individual and community health. The journal features papers that address the primary and secondary prevention of important clinical, behavioral and public health issues such as injury and violence, infectious disease, women's health, smoking, sedentary behaviors and physical activity, nutrition, diabetes, obesity, and alcohol and drug abuse. Papers also address educational initiatives aimed at improving the ability of health professionals to provide effective clinical prevention and public health services. The journal also publishes official policy statements from the two co-sponsoring organizations, health services research pertinent to prevention and public health, review articles, media reviews, and editorials. www.ajpmonline.org 打開新的分頁／視窗

關於 Elsevier

身為科學資訊與分析的全球領導者，Elsevier 協助研究人員與醫療照護專業人員推動科學發展，改善醫療成果，造福社會。我們以可信賴、以實證為基礎的內容和先進的 AI 數位技術為基礎，透過創新的解決方案促進洞察力和關鍵決策。

140 多年來，我們一直為研究和醫療保健界的工作提供支援。我們全球 9,500 名員工，包括 2,500 名技術人員，致力於支援研究人員、圖書館館長、學術領袖、資金提供者、政府、研發密集型公司、醫生、護士、未來醫療保健專業人員和教育工作者的重要工作。我們的 2,900 種科學期刊和經典參考工具書包括其領域中最重要的書籍，包括 Cell Press、The Lancet 和 Gray's Anatomy。 我們與愛思唯爾基金會 (Elsevier Foundation 打開新的分頁／視窗) 合作，與我們服務的社群攜手合作，在發展中國家和世界各地的科學、研究和醫療保健領域推動包容性和多樣性。 Elsevier 是 RELX 打開新的分頁／視窗 的一部分，RELX 打開新的分頁／視窗 是一家為專業和商業客戶提供以資訊為基礎的分析和決策工具的全球供應商。有關我們的工作、數位解決方案和內容的更多資訊，請造訪 www.elsevier.com 。